Have a feature idea you'd love to see implemented?
Let us know!
OCUL Ocular Therapeutix Inc
Price (delayed)
$9.23
Market cap
$1.44B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.11
Enterprise value
$1.05B
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation
Highlights
The revenue has grown by 12% YoY and by 2.1% from the previous quarter
Ocular Therapeutix's gross profit has increased by 11% YoY
The net income has dropped by 52% year-on-year and by 20% since the previous quarter
Ocular Therapeutix's quick ratio has decreased by 22% QoQ
Key stats
What are the main financial stats of OCUL
Market
Valuations
Earnings
Shares outstanding
155.92M
Market cap
$1.44B
Enterprise value
$1.05B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.79
Price to sales (P/S)
25.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.23
Revenue
$61.1M
EBIT
-$123.54M
EBITDA
-$119.81M
Free cash flow
-$90.59M
Per share
Balance sheet
Liquidity
EPS
-$1.11
Free cash flow per share
-$0.55
Book value per share
$2.44
Revenue per share
$0.37
TBVPS
$3.12
Total assets
$517.09M
Total liabilities
$139.4M
Debt
$74.89M
Equity
$377.7M
Working capital
$468.61M
Debt to equity
0.2
Current ratio
16.64
Quick ratio
16.4
Net debt/EBITDA
3.23
Margins
Efficiency
Dividend
EBITDA margin
-196.1%
Gross margin
90.8%
Net margin
-226.5%
Operating margin
-187.4%
Return on assets
-37.6%
Return on equity
-62.6%
Return on invested capital
-121.7%
Return on capital employed
-25.4%
Return on sales
-202.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OCUL stock price
How has the Ocular Therapeutix stock price performed over time
Intraday
-0.86%
1 week
5.13%
1 month
10.54%
1 year
203.62%
YTD
106.95%
QTD
6.09%
Financial performance
How have Ocular Therapeutix's revenue and profit performed over time
Revenue
$61.1M
Gross profit
$55.5M
Operating income
-$114.47M
Net income
-$138.36M
Gross margin
90.8%
Net margin
-226.5%
The net income has dropped by 52% year-on-year and by 20% since the previous quarter
The net margin has contracted by 36% YoY and by 18% from the previous quarter
The operating income has contracted by 36% YoY and by 25% from the previous quarter
Ocular Therapeutix's operating margin has decreased by 23% from the previous quarter and by 22% YoY
Growth
What is Ocular Therapeutix's growth rate over time
Valuation
What is Ocular Therapeutix stock price valuation
P/E
N/A
P/B
3.79
P/S
25.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.23
The company's EPS rose by 4.3% YoY
OCUL's price to book (P/B) is 84% less than its 5-year quarterly average of 23.9 and 64% less than its last 4 quarters average of 10.4
The equity has declined by 7% since the previous quarter
The stock's P/S is 104% above its last 4 quarters average of 12.3
The revenue has grown by 12% YoY and by 2.1% from the previous quarter
Efficiency
How efficient is Ocular Therapeutix business performance
Ocular Therapeutix's return on equity has surged by 84% YoY and by 31% QoQ
The return on assets has grown by 42% year-on-year and by 12% since the previous quarter
The company's return on sales fell by 33% YoY and by 19% QoQ
OCUL's return on invested capital is down by 17% since the previous quarter and by 14% year-on-year
Dividends
What is OCUL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OCUL.
Financial health
How did Ocular Therapeutix financials performed over time
The current ratio has contracted by 22% from the previous quarter
Ocular Therapeutix's quick ratio has decreased by 22% QoQ
The debt is 80% less than the equity
The company's debt to equity has shrunk by 99% YoY but it rose by 11% QoQ
The debt has grown by 16% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.